NCT03396068View on ClinicalTrials.gov

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Bipolar DepressionSuicidal Ideation
Interventions
DRUG

NRX-101

NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth

DRUG

Lurasidone HCl

Lurasidone HCl will be given twice a day by mouth

Trial Locations (4)

33024

Research Centers of America, Hollywood

35294

Research Site, Birmingham, Birmingham

76104

JP Smith Hospital, Fort Worth

77030

Research Site, Houston, Houston

Sponsors

Lead Sponsor

NeuroRx, Inc.
All Listed Sponsors
collaborator

Target Health Inc.

INDUSTRY

lead

NeuroRx, Inc.

INDUSTRY

NCT03396068 - NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation | Biotech Hunter | Biotech Hunter